Compound 8918 is an orally active, non-cytotoxic, phosphopantethein (Ppt)-binding pocket-targeting, non-competitive M. tuberculosis (Mtb) Ppt transferase (PptT) inhibitor (IC50 = 2.5 μM, Emax 80-90%) th at exhibits mycobactericidal activity (MIC90 = 0.56-3 μM/29 clinical Mtb isolates; MBC99 = 6.25 μM/Mtb, 3.13 μM/M. smegmatis) with no bactericidal potency against S. aureus, E. coli, P. aeruginosa, Streptomyces or C. albicans. Oral administration is efficacious against H37Rv replication in mouse lung in vivo (by 100%; 100 mg/kg/d, 4 d/wk for 2 wks). Mutations in MtbH37Rv rv2794c (PptT) or rv279c (Ppt hydrolase, PptH) gene confers 8918 resistance.
